Are you aged 18-30 with Type 1 diabetes and a body mass index ≥27kg/m2?

If you are aged 18-30 with type 1 diabetes for over a year and a body mass index ≥27kg/m2, you may be eligible to participate in a study to see how semaglutide (the study drug) impacts metabolic health in young adults who have both type 1 diabetes (T1D) and an elevated body mass index. This type of medication helps blood sugars, heart, and kidneys in adults with type 2 diabetes (T2D) and is included in comprehensive treatment guidelines for T2D.

After the initial screening, you will be asked to participate in 4 metabolic studies/visits that range from one to seven hours in duration. Some of these visits may be combined. Blood draws and magnetic resonance imaging are involved.

Eligible participants will be randomized into 1 of 2 study groups: active semaglutide (2/3 chance) or placebo (1/3 chance) and have intermittent visits during this 52-week treatment phase.

Compensation up to $1115, including $90 allotted for parking at study sites as needed.